Saros Therapeutics Inc.

Chicago, IL

UEI
HGU2SLP22BK2
CAGE
9BJR9
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
1375 W Fulton St Suite 650, Chicago, IL 60607, USA
Website
sarostx.com
Founded
2021
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Saros Therapeutics Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Demonstrating safety and combination therapy potential of a novel nanoparticle delivery system - summary… Grant · R44CA306545 National Cancer Institute $1,164,203
Process development and preclinical advancement of a novel nanoparticle formulation for immune activation - summary… Grant · R44CA281497 National Cancer Institute $2,046,919

Quick answers

What is Saros Therapeutics Inc.'s UEI?

Saros Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is HGU2SLP22BK2.

What is Saros Therapeutics Inc.'s CAGE code?

Saros Therapeutics Inc.'s CAGE code is 9BJR9.

What is Saros Therapeutics Inc.'s primary NAICS code?

Saros Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Saros Therapeutics Inc. located?

Saros Therapeutics Inc.'s physical address in SAM.gov is 1375 W Fulton St Suite 650, Chicago, IL 60607, USA.

Is Saros Therapeutics Inc. registered in SAM.gov?

Yes. Saros Therapeutics Inc.'s SAM.gov registration is active through January 2, 2027.

What is Saros Therapeutics Inc.'s most recent federal award?

Saros Therapeutics Inc.'s most recent federal grant award is Demonstrating safety and combination therapy potential of a novel nanoparticle delivery system - summary… (R44CA306545), from National Cancer Institute, on September 1, 2026.

On GovTribe

See Saros Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login